Condition: Endometrial Cancer · Endometrioid Tumor · Cancer · Sponsor: Aadi Bioscience, Inc.
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
This description comes directly from the study's public registry record.
Aadi Bioscience Medical Information · 1-888-246-2234 · MedInfo@aadibio.com
Always discuss trial participation with your own doctor first.
| Michael Birrer, MD, PhD | Little Rock, Arkansas, United States | Recruiting |
| Mount Sinai Comprehensive Cancer Center | Miami Beach, Florida, United States | Recruiting |
| Women's Cancer Center of Nevada | Las Vegas, Nevada, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Levine Cancer Institute | Charlotte, North Carolina, United States | Recruiting |
| Oklahoma University Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | Recruiting |
| Women & Infants Hospital | Providence, Rhode Island, United States | Recruiting |
| Texas Oncology - Tyler | Tyler, Texas, United States | Recruiting |
| Swedish Cancer Institute | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05997017